Ambiotis is a research-based company specialized in the field of inflammation with a thorough understanding of the resolution phase of this process.
Ambiotis develops validated experimental models and technologies to bring the proofs of concept and decipher mechanisms of action of drug candidates for our business partners and help them to put faster on the market new and innovative anti-inflammatory and pro-resolutive drugs.
Ambiotis has the ability to set up full research programs from screening assays up to monitoring of biomarkers in clinical trials.
Why Evaluate Anti-Inflammatory Drugs?
Inflammation is a natural response of the body to injury or infection. If correctly controlled, it leads to the complete restoration of the targeted tissue.
This return to basal conditions is called resolution and is characterized by the natural and sequential synthesis of specialized pro-resolving mediators (resolvins, protectins, lipoxins, maresins), or SPMs. These mediators are essential to induce correct healing and prevent fibrosis and chronic inflammation.
SPMs have known biological and beneficial activities in many inflammatory contexts including skin, neurodegenerative diseases, respiratory disorders, infections and more.
Current therapeutic molecules attempt to inhibit pathways leading to the production of pro-inflammatory mediators.
Continuous characterization of the resolution process is considerably changing the vision of drug development. It may indeed be possible to develop agonists of resolution pathways to fight chronic inflammation.
In addition, incorporating the evaluation of activities on resolution of anti-inflammatory drugs will also be necessary to avoid a resolution-toxic behaviour.
Ambiotis Has Developed a Step-by-Step Approach on Anti-Inflammation and/or Pro-Resolution Strategies
Any step can also be performed independently.
- In vitro screening of drug potential (secretory and functional approaches in human primary cells)
- In vivo proof-of-concept: Use of very well characterized and reference models in the field. Our experimental models allow the understanding of the physiological response to a drug and quantification of beneficial effects using the calculation of resolution indices.
- In disease experimental models and/or human monitoring of resolution mediators:
- Translational approaches
- Disease biomarker monitoring
- Efficacy biomarker monitoring